Similar articles

• VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice.

  Ou XM, Li WC, Liu DS, Li YP, Wen FQ, Feng YL, Zhang SF, Huang XY, Wang T, Wang K, Wang X, Chen L. Ou XM, et al. Int Immunopharmacol. 2009 Jan;9(1):70-9. doi: 10.1016/j.intimp.2008.10.002. Epub 2008 Oct 29. Int Immunopharmacol. 2009. PMID: 18976720
• Epigallocatechin-3-gallate exhibits anti-fibrotic effect by attenuating bleomycin-induced glycoconjugates, lysosomal hydrolases and ultrastructural changes in rat model pulmonary fibrosis.

  Sriram N, Kalayarasan S, Sudhandiran G. Sriram N, et al. Chem Biol Interact. 2009 Jul 15;180(2):271-80. doi: 10.1016/j.cbi.2009.02.017. Epub 2009 Mar 20. Chem Biol Interact. 2009. PMID: 19497426
• Diallyl sulfide attenuates bleomycin-induced pulmonary fibrosis: critical role of iNOS, NF-kappaB, TNF-alpha and IL-1beta.

  Kalayarasan S, Sriram N, Sudhandiran G. Kalayarasan S, et al. Life Sci. 2008 Jun 6;82(23-24):1142-53. doi: 10.1016/j.lfs.2008.03.018. Epub 2008 Apr 4. Life Sci. 2008. PMID: 18462759
• Bleomycin and pulmonary toxicity.

  Van Barneveld PW, Mulder NH, Van der Mark TW, Sleijfer DT. Van Barneveld PW, et al. Neth J Med. 1985;28(11):516-23. Neth J Med. 1985. PMID: 2417127 Review. No abstract available.
• Bleomycin lung toxicity: who are the patients with increased risk?

  Azambuja E, Fleck JF, Batista RG, Menna Barreto SS. Azambuja E, et al. Pulm Pharmacol Ther. 2005;18(5):363-6. doi: 10.1016/j.pupt.2005.01.007. Pulm Pharmacol Ther. 2005. PMID: 15939315 Review.